PerioGene North is a multicenter case-control study consisting of 526 periodontitis cases and 532 periodontally healthy controls that was collected through the years 2007-2019 by periodontists in northern Sweden. All participants have undergone a complete oral and periodontal examination, and a venomous blood sample was collected in conjunction with the oral examination. Periodontitis is an inflammatory and destructive oral condition with a complex etiopathology. Several factors impact development and progression of periodontitis which generates substantial differences in individual susceptibility and rate of tissue degradation. The mechanisms that underlie these inter-individual differences remain unclear and there is a need for diagnostic tools that will aid clinicians with risk assessment. Moreover, periodontitis has been associated to increased levels of serum inflammatory markers and linked to a range of comorbidities. Periodontitis share inflammatory pathways with several other inflammatory diseases. Therefore, identification of biomarkers which associates to the risk of developing comorbidities should be possible. There are currently no genetic- orbiomarkers available to predict onset of periodontitis, identify individuals at risk of a more aggressive disease course, or those at increased risk of related comorbidities. The purpose of PerioGene North is to increase our knowledge of periodontitis etiopathology and possible effects on general health as well as try to identify possible targets for biomarkers. To assess the aims, we will study risk factors for periodontitis, serum levels of proinflammatory cytokines and genetic risk factors in PerioGene North. Serum inflammatory markers has been analyzed with a DNA-based proximity extension assay (Olink Target 48 Cytokine Panel). High-sensitivity CRP (hs-CRP) levels were assessed by using a V-PLEX Human C-reactive protein (CRP) Kit on a Mesoscale platform. All serum analysis in PerioGene North was executed by SciLife Lab, which is a national research infrastructure provided by Uppsala University. Information about general heath has been collected from the National Board of Health and Welfare. We apply for usage of BIANCA to perform genetic analyses of the PerioGene North cohort. The analysis will be performed by NBIS in Uppsala